CORONA Remedies starts additional commercial production of tablets at Bhayla facility

22 Dec 2025 Evaluate

CORONA Remedies has successfully commenced the additional commercial production of tablets/capsules at the Bhayla manufacturing facility (Facility) of the company. As on March 31, 2025, the Facility has an installed capacity of 852.80 million with the available capacity of 600 million and actual production of 561.49 million which is equivalent to capacity utilization of 93.58%. The additional production will raise the installed capacity by 400 million and available capacity by 240 million at the Facility. 

The additional commercial production will add a significant milestone in the company’s strategic expansion to augment the upcoming market demands, enhance the in-house production capabilities and improve the supply chain agility. The commercialized additional capacity is entirely being funded through internal accruals. 

Corona Remedies is an India-focused branded pharmaceutical formulation company engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabeto, pain management, urology and other therapeutic areas.


CORONA Remedies Share Price

1347.25 -15.40 (-1.13%)
24-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1737.50
Dr. Reddys Lab 1266.35
Cipla 1496.35
Zydus Lifesciences 917.45
Lupin 2109.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×